EMERYVILLE, Calif.,
June 8 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will
present at Goldman Sachs 31st Annual Global Healthcare Conference
on Tuesday, June 15, 2010 at
4:55 p.m. Eastern Time (1:55 p.m. Pacific Time).
Interested parties may access a live webcast of the presentation
on our website at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
It is recommended that listeners log on 15 minutes early in
order to register and download any necessary software. For
those unable to participate during the live webcast, a recorded
replay of the presentation will be available within 24 hours of the
completion of the presentation through June
29, 2010.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company
committed to improving the lives of people with cancer. The
company, in collaboration with Bayer HealthCare Pharmaceuticals,
Inc., is developing and marketing Nexavar® (sorafenib) tablets, a
small molecule drug that is currently approved for the treatment of
liver cancer and advanced kidney cancer. Additionally, Nexavar is
being investigated in several ongoing trials in a variety of tumor
types. Beyond Nexavar, Onyx has established a development pipeline
of anticancer compounds at various stages of clinical testing,
including carfilzomib, a next-generation proteasome inhibitor, that
is currently being evaluated in multiple clinical trials for the
treatment of patients with relapsed or relapsed/refractory multiple
myeloma and solid tumors. ONX 0801, a targeted alpha-folate
inhibitor, and ONX 0912, an oral proteasome inhibitor, are
currently in Phase 1 testing. For more information about Onyx,
visit the company's website at www.onyx-pharm.com.
SOURCE Onyx Pharmaceuticals, Inc.